Science Explorer Back to mapMap
Discussion
Company · Charleroi · Belgium

Novasep (Belgium)

novasep.comROR OpenAlex
Research works
6
fractional, all time
Citations
263
41.4 per fractional work
Top-10% rate
19.7%
all institutions 10.0%
Open access
8%
world 40%
International
27%
world 18%
Novasep (Belgium)

Not ranked overall: Novasep (Belgium) is under the volume floor below which a citation excellence rate is noise. Not ranked is not the same as ranked last.

Which fields of science does Novasep (Belgium) work in?

In all years, 43% of research at Novasep (Belgium) is in Life Sciences, 36% in Health Sciences. Its largest fields are Medicine (36%), Biochemistry, Genetics and Molecular Biology (32%), Social Sciences (11%). It does 1.4× the world's share of Life Sciences.

Life Sciences: 3 fractional works · 42.8% of its workBiochemistry, Genetics and Molecular Biology: 2 fractional works · 31.7% of its workMolecular Biology: 1 fractional works · 22.7% of its workGenetics: 0 fractional works · 7.9% of its workEndocrinology: 0 fractional works · 1.1% of its workAgricultural and Biological Sciences: 0 fractional works · 5.2% of its workAnimal Science and Zoology: 0 fractional works · 5.2% of its workImmunology and Microbiology: 0 fractional works · 3.3% of its workImmunology: 0 fractional works · 3.3% of its workPharmacology, Toxicology and Pharmaceutics: 0 fractional works · 2.7% of its workPharmacology: 0 fractional works · 2.7% of its workHealth Sciences: 2 fractional works · 36.2% of its workMedicine: 2 fractional works · 36.2% of its workInfectious Diseases: 0 fractional works · 7.4% of its workEpidemiology: 0 fractional works · 5.4% of its workPublic Health, Environmental and Occupational Health: 0 fractional works · 5.2% of its workRadiology, Nuclear Medicine and Imaging: 0 fractional works · 5.2% of its workHepatology: 0 fractional works · 4.1% of its workHematology: 0 fractional works · 3.5% of its workGenetics: 0 fractional works · 1.7% of its workImmunology and Allergy: 0 fractional works · 1.6% of its workOncology: 0 fractional works · 1.6% of its workPathology and Forensic Medicine: 0 fractional works · 0.8% of its workSocial Sciences: 1 fractional works · 15.7% of its workSocial Sciences: 1 fractional works · 10.6% of its workCultural Studies: 0 fractional works · 5.2% of its workEducation: 0 fractional works · 5.2% of its workSmaller subfields together: 0 fractional works · 0.2% of its workArts and Humanities: 0 fractional works · 5.2% of its workLiterature and Literary Theory: 0 fractional works · 5.2% of its workPhysical Sciences: 0 fractional works · 5.2% of its workEngineering: 0 fractional works · 5.2% of its workBiomedical Engineering: 0 fractional works · 5.2% of its workALL ITS WORKNovasep (Belgium)6fractional works, all years
Life Sciences43%Physical Sciences5%Health Sciences36%Social Sciences16%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 8 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology231.7%
    2. Agricultural and Biological Sciences05.2%
    3. Immunology and Microbiology03.3%
    4. Pharmacology, Toxicology and Pharmaceutics02.7%
    1. Medicine236.2%
    1. Social Sciences110.6%
    2. Arts and Humanities05.2%
    1. Engineering05.2%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

    What are the most cited papers from Novasep (Belgium)?

    The most cited paper from Novasep (Belgium) is "Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young Adults" (Etienne Marc Sokal, Karel Hoppenbrouwers, Corinne Vandermeulen et al., 2007), with 431 citations. Next come "Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults" (181) and "Large-scale monoclonal antibody purification by continuous chromatography, from process design to scale-up" (75).

    Most cited papers
    #PaperReleasedCitations
    1 Recombinant gp350 Vaccine for Infectious Mononucleosis: A Phase 2, Randomized, Double‐Blind, Placebo‐Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of an Epstein‐Barr Virus Vaccine in Healthy Young Adults Etienne Marc Sokal, Karel Hoppenbrouwers, Corinne Vandermeulen et al. · The Journal of Infectious Diseases Open access 5 Dec 2007 431
    2 Phase I/II studies to evaluate safety and immunogenicity of a recombinant gp350 Epstein–Barr virus vaccine in healthy adults Michel P. Moutschen, Philippe Léonard, Etienne Marc Sokal et al. · Vaccine 19 Apr 2007 181
    3 Large-scale monoclonal antibody purification by continuous chromatography, from process design to scale-up Valérie Girard, Nicolas-Julian Hilbold, Candy K.S. Ng et al. · Journal of Biotechnology 8 May 2015 75
    4 Characterization of Wild-Type Recombinant Bet v 1a as a Candidate Vaccine against Birch Pollen Allergy Thierry Batard, A. Didierlaurent, Henri Chabre et al. · International Archives of Allergy and Immunology 2005 46
    5 Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02V-adjuvanted hepatitis B vaccine Murielle Surquin, Christian L. Tielemans, Imre Kulcsár et al. · Kidney International Open access 25 Nov 2009 37
    All 16 most cited papers, with filters and sorting

    Which research topics does Novasep (Belgium) publish most on?

    By volume: Virus-based gene therapy research, Viral Infectious Diseases and Gene Expression in Insects, Biofuel production and bioconversion and Protein purification and stability.

    Virus-based gene therapy…0Virus-based gene therapy research: 0 fractional worksViral Infectious Disease…0Viral Infectious Diseases and Gene Expression in Insects: 0 fractional worksBiofuel production and bioconversion: 0 fractional worksProtein purification and stability: 0 fractional worksFungal and yeast genetic…0Fungal and yeast genetics research: 0 fractional worksLiterature, Musicology, and Cultural Analysis: 0 fractional worksContemporary art, education, critique: 0 fractional worksParvovirus B19 Infection…0Parvovirus B19 Infection Studies: 0 fractional worksAnimal Virus Infections Studies: 0 fractional worksPolyamine Metabolism and Applications: 0 fractional works
    GeneticsMolecular BiologyBiomedical EngineeringEducation3 others

    Area is fractional works; colour is the subfield each topic belongs to.

    1. 1 Virus-based gene therapy research Genetics 0 works
    2. 2 Viral Infectious Diseases and Gene Expression in Insects Molecular Biology 0 works
    3. 3 Biofuel production and bioconversion Biomedical Engineering 0 works
    4. 4 Protein purification and stability Molecular Biology 0 works
    5. 5 Fungal and yeast genetics research Molecular Biology 0 works
    6. 6 Literature, Musicology, and Cultural Analysis Education 0 works
    7. 7 Contemporary art, education, critique Cultural Studies 0 works
    8. 8 Parvovirus B19 Infection Studies Infectious Diseases 0 works
    9. 9 Animal Virus Infections Studies Animal Science and Zoology 0 works
    10. 10 Polyamine Metabolism and Applications Molecular Biology 0 works

    How open and international is its research?

    Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

    openly available7.8%not open92.2%

    World: 40% of research is openly available.

    with international co-authors26.6%domestic only73.4%

    World: 18% is written across borders.

    How has Novasep (Belgium)'s research output changed?

    200520102015
    grewheldshrank

    The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

    Its share of all research

    Growing output can still be a shrinking share: all of science grows. This is Novasep (Belgium) as a percentage of every work published that year, 0.0000025% in 2011.

    0.000050%0.00010%Novasep (Belgium)0.000027% in 20152010

    Fractional works of Novasep (Belgium) over all fractional works that year. How the balance of science has shifted.

    Other research institutions in Charleroi

    All research institutions in Charleroi

    Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

    Discussion

    Ask a question or share a note about Novasep (Belgium). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.